在史蒂文斯-约翰逊综合征/有毒表皮解毒症治疗中,阿达利穆马布与皮质类固醇治疗的结合
Jia Liu1, Mengyun Zhou1, Taoye Li2
1Department of Dermatology, Hangzhou Third People's Hospital, Hangzhou, 310009, China.
Archives of dermatological research
|April 10, 2025
概括
将阿达利穆马布与皮质类固醇结合使用,为史蒂文斯-约翰逊综合征/有毒表皮解 (SJS/TEN) 提供了优越的治疗方法. 这种方法可以减少住院和康复时间,而不会增加不良事件或死亡率.
科学领域:
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 史蒂文斯-约翰逊综合征/有毒表皮解 (SJS/TEN) 是一种严重的粘膜皮肤反应,死亡率高.
- 目前的治疗方法,如皮质类固醇和IVIG有局限性.
- 瘤亡因子-α (TNF-α) 抗剂显示出潜在的治疗益处.
研究的目的:
- 为了比较阿达利穆马布加上皮质类固醇的有效性和安全性与SJS/TEN的传统疗法.
- 评估结果,包括住院时间,重新表皮化时间和不良事件.
主要方法:
- 一个单一中心,回顾性,观察性研究,涉及53名SJS/TEN患者.
- 患者接受传统疗法 (皮质类固醇和IVIG) 或组合疗法 (阿达利穆马布和皮质类固醇).
- 主要终点:住院时间和重新上皮化时间. 二级终点:高剂量类固醇暴露和不良事件发生率.
主要成果:
- 与传统疗法相比,组合疗法显著减少了住院时间 (22 vs. 25 天) 和重新上皮化时间 (17 vs. 19 天).
- 组合组显示,高剂量类固醇 (16 vs. 18天) 的暴露减少,并在出院时显著降低TNF-α水平.
- 在退院后6个月内,两组之间没有观察到重大不良事件发生率或死亡率的显著差异.
结论:
- 与阿达利穆马布和皮质类固醇的联合治疗似乎是SJS/TEN的最佳治疗方法.
- 这种方法可以促进更快的疾病恢复,而不会增加不良事件或死亡率.
- 需要进一步的研究来证实这些发现,并建立最佳的治疗方案.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
108
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
108
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
91
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
91
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
103
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
103
Drugs for Treatment of Ulcerative Colitis in IBD
109
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
109
Inflammatory Bowel Disease IV: Pharmacological Management
82
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
82
Clinical Applications of Epidermal Stem Cells
2.7K
Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own...
2.7K


